Mesothelioma | Mesothelioma news | Breaking lung cancer news | Mesothelioma

News

Advertisers:

Hana begins second stage study of Talotrexin

...Advertisement The primary objective of this open-label study is to demonstrate an improvement in overall survival.

Secondary objectives are evaluation of safety, overall response rate, time to progression, and progression free survival.

Relapsed or refractory non-small cell Patients who meet all eligibility criteria will receive Talotrexin (PT-523) on a 21-day cycle.

Myelosuppresion and mucositis were the dose limiting toxicities of the preceding phase I portion of the trial that determined the recommended phase II dose of Talotrexin in this setting.

"Antifolates clearly have a role in the management of advanced non-small cell These preliminary data are encouraging and support taking this drug into the phase II setting," said Dr Jennifer Garst, assistant professor of medicine at Duke University, and an investigator on the trial commented.

RELATED NEWS Hana initiates trials of oral spray14 Dec 2005 GlaxoSmithKline: Zofran sales set for off-Par performance22 Nov 2005 Hana initiates trial of talotrexin in leukemia patients13 May 2005 Hana Biosciences initiates trial of anticancer compound9 Sep 2005 Hana Biosciences receives $159,000 for cancer drug studies9 Aug 2005 COMPANIES MENTIONED No companies found YOUR OPINION...